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To characterize the effect(s) of transforming growth factor alpha (TGFa) during multistage carcinogenesis,
we examined tumor development in pancreas and liver of transgenic mice that coexpressed TGFaL with either
viral (simian virus 40 T antigens [TAg]) or cellular (c-myc) oncogenes. In pancreas, TGFa itself was not
oncogenic, but it nevertheless dramatically accelerated growth of tumors induced by either oncogene alone,
thereby reducing the host life span up to 60%. Coexpression of TGFa and TAg produced an early synergistic
growth response in the entire pancreas together with the more rapid appearance of preneoplastic foci.
Coexpression ofTGFar and c-myc also accelerated tumor growth in situ and produced transplantable acinar cell
carcinomas whose rate of growth was TGFa dependent. In liver, expression of TGFax alone increased the
incidence of hepatic cancer in aged mice. However, coexpression of TGFa with c-myc or TAg markedly
reduced tumor latency and accelerated tumor growth. Significantly, expression of the TGFat and myc
transgenes in hepatic tumors was induced up to 20-fold relative to expression in surrounding nonneoplastic
liver, suggesting that high-level overexpression of these proteins acts as a major stimulus for tumor
development. Finally, in both pancreas and liver, combined expression of TGFa and c-myc produced tumors
with a more malignant (less differentiated) appearance than did expression of c-myc alone, consistent with an
influence of TGFa upon the morphological character of c-myc-induced tumor progression. These findings
demonstrate the importance ofTGFa expression during multistage carcinogenesis in vivo and point to a major
role for this growth factor as a potent stimulator of tumor growth.
The development of cancer is widely viewed as a progres-
sion of events during which affected cells gradually escape
normal restrictions upon growth and mobility. Specific ge-
netic and epigenetic lesions have now been associated with
this process (5). For some of these lesions, including activa-
tion of proto-oncogenes and inactivation of tumor suppres-
sor genes, a causal contribution to cancer has been demon-
strated (17, 26, 52). For other lesions, the contribution has
not been as clearly defined. An example of the latter is
enhanced production by tumor cells of transforming growth
factor alpha (TGFa).
TGFa is a member of the epidermal growth factor super-
family of polypeptide mitogens, and it binds to and activates
the epidermal growth factor receptor (EGFR) (reviewed in
references 9, 23, and 29). TGFa protein and mRNA have
been detected in preimplantation embryos (33) and midges-
tation fetuses (53) as well as in a variety of adult tissues (9,
23). The precise physiological functions of TGFot are pres-
ently unknown, but this growth factor has been shown to
regulate cellular proliferation, migration, and differentiation
in vitro (9, 23).
Although TGFa is expressed by a variety of normal
tissues, its expression is most prevalent and abundant in
both spontaneous and experimental tumors and in trans-
formed cell lines. For example, diffuse TGFa immunoreac-
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tivity was detected in epithelium of 80 of 84 human pancre-
atic adenocarcinomas (3). Additionally, TGFa is produced
by several human pancreatic adenocarcinoma cell lines, and
it reportedly can enhance their growth in culture via auto-
crine or paracrine mechanisms (20, 30, 45). Similarly, trans-
formed rodent liver epithelial cells overexpress TGFa (13,
21, 22, 24, 34), and increased levels ofTGFa can be detected
in the urine of patients diagnosed with hepatocellular carci-
noma (54). Other tumors, including squamous, renal, and
mammary carcinomas, often express elevated levels of
TGFa mRNA (11), as do transformed epithelial cell lines
derived from mammary gland (1, 4, 49), colon (19), prostate
(16), and skin (35). These observations have been widely
interpreted as suggesting that deregulated expression of
TGFa contributes to the development of cancer, and this
suggestion has been corroborated by demonstrations that
TGFax can induce the transformed phenotype in cultured
fibroblasts (6, 36, 51) and mammary epithelial cells (28, 43).
However, the extent to which expression of TGFa can
directly influence the development of cancer in vivo has not
yet been fully determined.
To address these and related issues, we previously created
transgenic mice carrying a fusion transgene that combined
the enhancer/promoter of mouse metallothionein-I (MT)
with the coding sequence of rat TGFa (37). MT-TGFa
transgenic mice displayed an increased incidence of mam-
mary cancer in postlactational females and of liver tumors in
older mice. Several founder males and all males in one
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TABLE 1. Transgenic mouse lines
Transgene (lineage)a Reference Relevant phenotype
In pancreas
MT-TGFa (1745-8) 37 Moderate to severe pancreatic hyperplasia, fibrosis, and pseudoductular metaplasia.
No tumors.
EL-TGFa (2262-5) 37 Moderate pancreatic hyperplasia, fibrosis, and pseudoductular metaplasia. No
tumors.
EL-TAg (264-4) 31 Death between 16 and 40 weeks of age due to development of multiple acinar cell
carcinomas.
EL-myc (1195-3) 38 Death between 12 and 30 weeks of age due to development of multiple acinar cell
and mixed acinar-ductal carcinomas.
In liver
MT-TGFa (1745-8) 37 Hepatic adenocarcinoma in 1 of 6 mice examined between 36 and 60 weeks of age.
AL-TAg (522-8) 39 Death between 12 and 18 weeks of age due to development of multiple solid,
trabecular, and cystic hepatic carcinomas.
AL-myc (741-3) 39 Well-differentiated hepatocellular adenomas in 4 of 6 mice examined between 62 and
100 weeks of age.
AL-myc (744-8) 39 Solid to trabeculat hepatocellular carcinomas in 3 of 6 mice examined between 70
and 100 weeks of age.
aPublished transgenic mouse lineage nomenclature is as follows: line 1745-8, Tg(Mt-1,Tgfa)Bril49; line 2262-5, Tg(Ela-1,Tgfa)Bril5l; line 264-4, Tg(Ela-
1,SV40E+Ela-1,neo)Bril9; line 1195-3, Tg(Ela-1,Myc)Bril59; line 522-8, Tg(Alb-1,SV40E)Bri82; line 741-3, Tg(Alb-1,Myc)Bri82; line 744-8, Tg(Alb-1,Myc)
Bri83.
MT-TGFa lineage developed hyperplastic nodules or adeno-
mas in the coagulation gland. In pancreas, deregulated
expression of TGFa did not induce neoplasia but did pro-
duce both marked fibroplasia and foci of- redifferentiated
acinar cells. In many organs, including liver and the gastro-
intestinal tract, high-level TGFa expression produced two-
to threefold increases in organ size and epithelial cell number
without otherwise altering tissue architecture. Similar find-
ings were reported by Jhappan et al. (18) for mice carrying an
MT-human TGFa fusion transgene. These studies thus con-
firmed TGFa's activity as a potent mitogen in vivo, partic-
ularly for epithelial cells, and clearly revealed that the effects
of deregulated TGFa production are tissue specific.
In this study, we have exploited this transgenic model to
further characterize TGFa's contribution to the develop-
ment of cancer by examining its ability to influence onco-
gene-induced carcinogenesis in pancreas and liver. We re-
port that coexpression of TGFa with either the simian virus
40 T antigens (TAg) or mouse c-myc dramatically enhances
tumor growth in both organs.
MATERIALS AND METHODS
Transgenic mice. The transgenic mice used in this study
have been previously described (31, 37-39), and their rele-
vant phenotypes are listed in Table 1. To generate mice
carrying two different transgenes, matings were established
between selected lines, and resulting offspring were
screened for transgenes by probing dot blots of tail DNA as
described previously (7). Mice were maintained in a
C57BL/6 x SJL genetic background. Expression of the MT
enhancer/promoter was induced by providing mice with 25
mM ZnSO4 in drinking water at or before the time of
weaning (3 to 4 weeks of age).
Tissue transplants. Pieces of pancreatic or hepatic tumors
3 to 5 mm3 in size were removed from transgenic mice,
placed into separate petri dishes containing 1 to 2 ml of
Dulbecco modified Eagle medium, and minced with sterile
iris, scissors. Each resulting suspension was drawn into a
syringe through an 18-gauge needle, and equal volumes were
injected subcutaneously between the scapulae of six 3-week-
old syngeneic mice. Three mice from each set were provided
with water containing ZnSO4 to induce MT-TGFa expres-
sion. Recipient mice were examined twice weekly to deter-
mine tumor latency (time from transplant until tumors were
first palpable) and tumor size. The latter was estimated by
measuring the two largest tumor axes with calipers and using
the formula for area of an oval to calculate maximal cross-
sectional area (A = irab, where a and b are hemiaxes).
Gross and histopathology. Mice were sacrificed when
moribund or at defined ages during tumor progression and
examined for gross lesions. Pancreas and/or liver were fixed
in 10% neutral buffered formalin, embedded in paraffin,
sectioned at 5 ,m, stained with hematoxylin and eosin, and
examined to determine histopathological diagnoses (25). The
total cross-sectional area of fixed pancreas sections was
determined by weighing pieces of uniform-weight graph
paper trimmed to fit the outline of each section. Immunohis-
tochemistry was performed as described previously (37),
using a rabbit antiserum raised against the cytoplasmic
domain of the TGFa precursor (kindly provided by Larry
Gentry).
RNA analyses. Quantitative solution hybridization was
carried out as previously described (12, 37). Values for liver
were calculated as molecules per diploid nucleus equivalent
because of the variation in nuclear ploidy in that organ. For
Northern (RNA) analyses, total RNA (10 pg) was electro-
phoresed through 1% agarose gels containing formaldehyde
and transferred to nitrocellulose, and blots were probed with
nick-translated cloned cDNA fragments as previously de-
scribed (37). Prior to Northern analysis, both the integrity
and relative concentrations of RNAs were confirmed by
electrophoresis through denaturing agarose-urea gels (14). In
situ analysis was performed on paraffin sections as described
previously (44), using a [35S]UTP-labeled TGFa riboprobe
derived from a 1.9-kb EcoRI-SalI restriction fragment of the
rat TGFa cDNA (6) in plasmid pGEM-4Z. Prior to hybrid-
ization, the riboprobe was partially digested in 0.2 M car-
bonate buffer (pH 10.2) at 60°C for 30 min. The specificity of
hybridization was confirmed in control hybridizations car-
ried out with sense-strand riboprobes.
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FIG. 1. Gross photograph of mouse pancreases. Each pancreas
was removed from a 9-week-old female mouse. The pancreases
were from a nontransgenic control (A), a mouse expressing the
EL-TAg transgene (B), and a mouse expressing both EL-TGFa (line
2262-5) and EL-TAg (C). See Table 1 for a description of the
transgenic lineages used in this cross. Identical results were ob-
served in the cross between MT-TGFa and EL-TAg.
RESULTS
TGFa and pancreatic carcinogenesis. We previously
showed that transgenic mice in which deregulated TGFa
expression was targeted to pancreas under the control of
either the MT or elastase (EL) enhancer/promoter (37)
displayed uniform pancreatic fibrosis and foci of duct-like
lesions characterized by redifferentiation of acinar cells.
Despite these alterations, only 1 of 31 mice examined at or
beyond 36 weeks of age had developed a pancreatic acinar
cell carcinoma (the affected mouse was from the highest-
expressing EL-TGFa lineage). In this report, we show that
although TGFao rarely induces pancreatic tumors alone, its
expression dramatically accelerates the development of tu-
mors induced in this organ by either TAg or c-myc.
Figure 1 shows pancreases removed from a 9-week-old
nontransgenic mouse (Fig. 1A) and littermates expressing
either EL-TAg alone (Fig. 1B) or both EL-TAg and EL-
TGFa (Fig. 1C). Upon gross examination of these mice, it
was immediately apparent that the TGFtiTAg-expressing
pancreas was much larger than both normal and TAg-
expressing pancreases, largely as the result of the presence
of multiple tumor nodules. By comparison, the pancreas
expressing TAg alone was only moderately larger than the
normal pancreas as a result of oncogene-induced hyperpla-
sia. We further observed that identical morphological
A
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changes accompanied coexpression of the MT-TGFax and
EL-TAg transgenes. Because MT-regulated TGFa expres-
sion is inducible by zinc (37), we chose to use the MT-TGFa
lineage mice in all subsequent analyses.
Accelerated tumor development in dual-positive mice
coexpressing TGFa and TAg was further reflected by the
remarkable finding that all mice bearing both transgenes died
before the first TAg single-positive mouse died, and those
deaths occurred over a shorter period of time (5 versus 20
weeks; Fig. 2A). The average survival of MT-TGFa x
EL-myc transgenic mice was also significantly reduced rel-
ative that of mice expressing EL-myc alone (Fig. 2B).
Subsequent analysis showed the cause of death in all groups
to be the development of multifocal pancreatic tumors.
Tumors present in MT-TGFa x EL-myc mice frequently
were composed of sheets of cells smaller and less differen-
tiated than those found in EL-myc-only tumors (compare
Fig. 3A and B). Additionally, most tumors induced by
EL-myc alone were mixed acinar-ductal adenocarcinomas,
with ductal changes being more abundant in tumors from
older mice (38). Ductal elements were not observed in
MT-TGFa x EL-myc tumors, although this observation may
simply reflect the reduced life span of these mice. In con-
trast, we did not observe a major influence of TGFa upon
TAg-induced tumor morphology. Finally, TGFa did not
obviously influence the vascularity or metastatic potential of
either TAg- or c-myc-induced tumors, as determined by
gross and histological examination of tumors and other
organs (data not shown).
To address the possibility that accelerated pancreatic
tumorigenesis resulted from TGFa-induced increases in on-
cogene expression, we compared steady-state levels of TAg
and c-myc transcripts in tumors isolated from single- and
dual-positive transgenic mice. Although there was a high
degree of intertumor variability, quantitative solution hy-
bridization assays revealed no significant differences be-
tween expression of c-myc in TGFa/c-myc tumors (mean +
standard error of the mean, 81 + 22; n = 5) versus c-myc-
only tumors (113 + 51; n = 2), or between expression of TAg
in TGFcTAg tumors (56 + 16; n = 11) versus TAg-only
tumors (28 + 8; n = 5). We also used in situ hybridization
analysis to determine that TGFa expression was generally
not induced in neoplastic TGFa/TAg tumor nodules relative
Age (weeks) Age (weeks)
FIG. 2. Survival of mice bearing pancreatic tumors. Percent survival as a function of age is shown in panel A for MT-TGFa x EL-TAg
and EL-TAg transgenic mice and in panel B for MT-TGFa x EL-myc and EL-myc transgenic mice. See Table 1 for a description of the
transgenic lineages used in these crosses. (A) n = 13 for TGFa x TAg and 16 for TAg only; (B) n = 15 for TGFcL x myc and 8 for myc only.
Dual-positive mouse survival is significantly reduced relative to that of the respective single-positive control for each pair at P < 0.00002,
using Student's t test.
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FIG. 3. Histopathology of pancreatic lesions. (A) Poorly differentiated acinar cell carcinoma in a 23-week-old EL-myc transgenic mouse.
(B) Solid, undifferentiated acinar cell carcinoma in a 13-week-old MT-TGFa x EL-myc transgenic mouse. (C) Normal pancreas from a
13-week-old nontransgenic control mouse. (D) Fibrotic pancreas from an 8-week-old MT-TGFa transgenic mouse. Note the separation
between most acini, caused by an increase in connective tissue, and the collection of duct-like elements (pseudoducts) to the right of center
that result from dilatation and altered differentiation of individual acini (37). A normal pancreatic duct is visible near the center of the
photograph (arrow). (E) Pancreas from a 12-week-old EL-TAg transgenic mouse. Dysplastic but nonneoplastic pancreas is present at the
upper left. A microcystic atypical acinar cell focus is present at the lower left; its border is indicated by arrowheads. (F) Pancreas from an
8-week-old MT-TGFa x EL-TAg transgenic mouse. A solid to cystic atypical acinar cell focus is present in the center, causing mild
compression of surrounding dysplastic pancreas. The scale bar in panel F represents 0.2 mm for all photographs.
to surrounding untransformed pancreas (data not shown).
These findings suggest that accelerated pancreatic tumori-
genesis is not simply the result of enhanced transgene
expression.
We examined pancreases from younger single- and dual-
positive mice to identify possible early changes that might
accompany or contribute to accelerated tumor formation.
Strikingly, a comparison of pancreatic weight as a fraction of
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FIG. 4. Postnatal pancreatic growth and kinetics of preneoplastic focus development. (A) Relative pancreatic weights were calculated by
expressing pancreatic weight as a fraction of total body weight and then plotted as a function of age for four groups of mice: MT-TGFa x
EL-TAg mice, MT-TGFa and EL-TAg single-positive mice, and nontransgenic control mice. Each point represents the mean of three to eight
measurements (except for 2-week TGFa-only, for which n = 2). All mice were administered ZnSO4 in drinking water from conception. Error
bars represent standard deviations. All values except those for 2-week TAg-only are significantly different from the corresponding control
value at P < 0.05, using Student's t test. All dual-transgenic values are also significantly different from the corresponding TAg-only value at
P < 0.05. (B) The numbers of preneoplastic foci per square centimeter of pancreatic cross-sectional area in dual- and single-positive transgenic
mice carrying the EL-TAg transgene were calculated as described in Materials and Methods and then plotted as a function of age. Each point
was determined by examining pancreatic cross sections of four to seven mice. All mice were administered ZnSO4 in drinking water from
conception. Distinct preneoplastic foci were not observed in pancreases of single-positive mice carrying only MT-TGFa.
total body weight versus age for young mice revealed that
whereas expression of either TGFa or TAg alone produced
a doubling of relative pancreatic weight, their coexpression
synergistically produced a sixfold increase (Fig. 4A). This
relative increase in pancreatic weight was essentially com-
plete by 4 weeks of age, and subsequent growth remained
proportional to body weight. Although in mice expressing
TGFa alone the increase in pancreatic weight was largely the
result of fibrosis (compare Fig. 3C and D) (37), MT-TGFa x
EL-TAg pancreases displayed limited fibrosis and, instead, a
large increase in the number of dysplastic acinar cells. This
alteration is similar to that observed in EL-TAg mice (com-
pare Fig. 3D, E, and F), suggesting that in pancreas, the TAg
phenotype is dominant over that of TGFa. A comparison of
the number of preneoplastic lesions (defined by loss of
typical acinar architecture; Fig. 3E and F) per unit cross-
sectional pancreatic area revealed that lesions were evident
at an earlier age in MT-TGFot x EL-TAg mice than in
EL-TAg mice, and the number of these lesions increased
more rapidly (Fig. 4B). Note that this analysis was not
continued beyond 10 weeks for dual-positive mice or 18
weeks for TAg-only transgenic mice, because after those
ages, animals in both groups often displayed one or more
large pancreatic tumor nodules that caused an unacceptable
data bias. Discrete, unequivocally preneoplastic foci were
not evident in EL-myc pancreases; thus, these mice were not
similarly analyzed.
The endpoints of the curves shown in Fig. 4B indicate a
fourfold increase in the number of foci per unit area detected
at a late stage of pancreatic preneoplasia in MT-TGFa x
EL-TAg mice versus EL-TAg single-positive mice. This
increase could result from enhanced initiation of foci or the
more rapid growth of foci (increasing their chance of being
identified and counted). The finding that dual-positive mice
began to die as the result of large pancreatic tumors only 4
weeks after the first small pancreatic foci were detected,
whereas the first deaths of TAg-only single-positive mice did
not occur until 8 weeks after the first foci were detected
(compare Fig. 2A and 4B), is consistent with an enhanced
growth of foci into tumors. To directly assess the effect of
TGFa on tumor growth, several individual primary tumor
nodules were removed from MT-TGFa x EL-myc trans-
genic mice, and minced suspensions of each nodule were
distributed subcutaneously among six syngeneic recipient
mice, three of which were induced for MT-TGFa expres-
sion. Growth of the resulting transplant nodules was mea-
sured twice weekly. As shown for three individual nodules in
Fig. 5 and summarized for a larger cohort in Table 2,
administration of ZnSO4 in drinking water, which generally
augmented expression of TGFa mRNA in subcutaneous
nodules without systematically affecting expression of the
EL-myc transgene, consistently reduced both tumor latency
(the time before a tumor became palpable) and the time
required for tumors to reach 100mm in cross-sectional area.
In contrast, zinc had no apparent effect on nodules express-
ing EL-myc alone (Table 2). A similar analysis was carried
out with tumors from MT-TGFa x EL-TAg dual-transgenic
mice. In these experiments, neither the latency nor growth
rates of subcutaneous tumors were uniformly influenced by
ZnSO4 treatment (data not shown). However, we also ob-
served no systematic increase in the level of either MT-
TGFa or endogenous MT mRNA in these tumors in re-
sponse to zinc, suggesting that the MT promoter was no
longer zinc responsive in end-stage TAg-induced tumors.
These results, although not excluding a contribution of
TGFa overexpression to enhanced tumor initiation, vividly
confirm the ability of induced TGFa expression to stimulate
tumor growth in vivo.
TGFat and hepatic carcinogenesis. Although transgenic
mice expressing TGFa alone did not show a significantly
increased incidence of pancreatic tumors, older transgenic
mice did display a higher incidence of hepatic tumors than
did nontransgenic controls. Of 27 mice from three MT-TGFa
lineages examined between 26 and 104 weeks of age, 16
displayed one or more hepatic tumors up to 2 cm in diame-
ter. Although most tumors did not appear malignant, three
A
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FIG. 5. Growth of transplanted tumor nodules. Maximal cross-sectional area of transplanted tumor nodules is plotted as a function of time
after transplant for tissue derived from three different primary tumors. Donor mice carried both the MT-TGFa and EL-myc transgenes. Tissue
from each primary tumor was transferred into six syngeneic mice, three of which were administered ZnSO4 in drinking water to induce
MT-TGFa expression. On average, tumors appeared earlier and grew more quickly in zinc-induced mice (solid lines). Data from these and
three additional transplant experiments are summarized in Table 2.
adenomas contained variably sized foci of carcinoma, two
tumors were diagnosed as hepatocellular carcinomas, and
one was diagnosed as a cholangiocarcinoma. Nine nodules
displayed large, dilated vascular spaces surrounded by nar-
row sheets of tumor parenchyma (Fig. 6A). In contrast, only
1 of 20 nontransgenic control mice had developed a 5-mm-
diameter benign hepatic tumor by 130 weeks of age.
As in pancreas, coexpression of TGFa and c-myc in liver
produced a dramatic, synergistic induction of tumors. Two
previously established transgenic mouse lines (741-3 and
744-8 [39]) in which c-myc expression was directed to
hepatocytes under control of the albumin (AL) enhancer/
promoter each displayed a comparable age-dependent inci-
dence of hepatic lesions (Table 1); two-thirds of these mice
developed one to three large tumors beginning at 62 weeks of
age. However, when 741-3 lineage AL-myc mice were
crossed with MT-TGFa mice and the offspring were induced
TABLE 2. Ratios of growth and transgene expression in EL-myc
x MT-TGFa transplant nodulesa
Mean + SEM (+Zn/-Zn)
Transgene (n)b Tumor Growth to mRNAd
latency 100 mm' TGFa myc
myc only (2) 0.93 ± 0.02 1.01 ± 0.25 1.26 ± 0.06W
myc x TGFa (6) 0.63 ± 0.10f 0.52 ± 0.13f 7.4 ± 3.2f 0.96 ± 0.15
a See Materials and Methods for a description of the procedure. Growth
characteristics and transgene expression of transplant nodules isolated from
different primary tumors vary greatly. However, nodules derived from
MT-TGFa x EL-myc tumors (though not EL-myc-only tumors) should
display zinc-inducible expression of the MT-TGFa transgene. Thus, data are
expressed as a ratio of measurements from zinc-induced (+Zn) versus
uninduced (-Zn) transplant nodules derived from the same primary tumor,
rather than as a ratio of measurements from transplant nodules derived from
TGFa/c-myc versus c-myc-only primary tumors.
b myc, EL-myc (Bri159); TGFoa, MT-TGFa (Bri149). Tumor incidence in
each group of recipient mice was 100%. One-millimeter pieces of pancreas
from an MT-TGFa mouse were also transplanted into three syngeneic
recipients given zinc, but all failed to grow.
c Time in days between first identification of a transplant nodule and its
attainment of 100-mm2 maximal cross-sectional area.
d Determined by quantitative solution hybridization analyses.
Significantly different from 1 atP < 0.05, using Student's t test to compare
meaningfully paired samples (+Zn/-Zn).
f Significantly different from 1 at P < 0.025, using Student's t test to
compare meaningfully paired samples (+Zn/-Zn).
for MT-TGFa expression, all dual-positive mice developed
up to 10 large, malignant-appearing hepatic tumors and died
or were moribund by 38 weeks of age (Fig. 7A). In contrast,
and consistent with our previous observations (39), litter-
mates expressing only the c-myc transgene that were sacri-
ficed at the same age displayed no neoplastic hepatic lesions.
Hepatic nodules observed in MT-TGFa x AL-myc trans-
genic mice included hyperplastic foci (15%), adenomas
(23%), and solid or trabecular carcinomas (62%) (Fig. 6B).
Most nodules were composed of immature-appearing hepa-
tocytes, and many contained numerous biliary-like cells
arranged in nests or streaks. The latter were not conspicuous
in tumors induced by c-myc alone, suggesting that TGFa
enhanced growth of bile duct epithelium. The malignant
character of dual-positive tumors was confirmed by demon-
strating their ability to grow rapidly when transplanted into
syngeneic hosts (data not shown). This rapid growth of
transplanted TGFailc-myc hepatic tumors contrasts with
previous experiments in which cells from only 1 of 10
transplanted hepatic tumors survived in syngeneic hosts.
Tumors previously examined included one from an AL-ras
mouse (39), one from an AL-ras x AL-myc dual-positive
mouse, four from AL-urokinase mice (40), and four from
AL-TAg mice (39); of these, only one of the latter grew
slowly in two of three recipients.
Significantly, all MT-TGFa x AL-myc tumors greatly
overexpressed the transgene relative to normal, surrounding
transgenic liver. Quantitative solution hybridization analy-
ses revealed an average 10-fold increase in TGFa transcripts
in tumors. Thus, whereas TGFa transcripts were present at
a level of 240 + 20 molecules per diploid nucleus equivalent
in untransformed liver (mean + standard error of the mean;
n = 5), the comparable value in tumors was 2,800 310
molecules per cell (n = 9). For comparison, endogenous MT
gene expression increased only twofold (150 + 12 [n = 4]
versus 300 + 16 [n = 7]). This induction of TGFa expression
was reflected further by the results of in situ hybridization
analyses, which clearly demonstrated elevated levels of
TGFot mRNA in tumors compared with adjacent untrans-
formed parenchyma (Fig. 6C). Finally, Northern blot analy-
sis both corroborated the results of in situ and solution
hybridization analyses and further demonstrated that the
increased levels of TGFa transcripts were the result of
enhanced expression of the transgene rather than of the
D0
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FIG.6Histopatholo.yand in situ hybridization analysis of hepatic lesions. (A) Solid to trabecular hepatocellular carcinoma in a
-4.
36-week-old MT-TGFa transgenic mouse. Note the large, dilated vascular spaces (some containing erythrocytes) that border the tumor
epithelium along three margins. (B) Trabecular hepatocellular carcinoma flanking and compressing nonneoplastic liver (upper right) in a
34-week-old MT-TGFa x AL-myc transgenic mouse. (C) Section adjacent to that in panel B incubated with an antisense riboprobe
complementaiy to TGFa mRNA. Note the marked increase in the number of silver grains overlying tumor cells (indicated by arrowheads)
relative to nonneoplastic hepatocytes. The tumor is also heterogeneous for TGFa expression. (D) A clear cell altered focus (center) in the liver
of the mouse represented in panels B and C. Note the dysplastic hepatocytes above and below the focus that display variable nuclear and
cytoplasmic size and staining characteristics. (E) A clear cell altered focus (bottom) and a focus of minimally altered cells with slightly dilated
sinusoids (top) in the liver of a 30-week-old MT-TGFa x AL-myc transgenic mouse. (F) Section adjacent to that in (E) incubated with an
antisense riboprobe complementary to TGFa mRNA. Note that the minimally altered focus (arrowheads) but not the clear cell focus displays
a marked increase in silver grains. The scale bar in each photograph represents 0.2 mm.
endogenous TGFa gene that gives rise to a larger transcript firm that in contrast to pancreas, induced TGFa transgene
(Fig. 8). Analysis offive independent tumors showed that the expression is a frequent event in this model of hepatic
increased expression of TGFa transcripts occurred in the carcinogenesis. We note that enhanced transgene expression
absence of increased transgene copy number relative to total was not limited to TGFCL, since most tumors also displayed
tumor DNA content. Hence, three independent assays con- a moderate to marked elevation in c-myc transgene expres-
MOL. CELL. BIOL.
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FIG. 7. Survival of mice bearing hepatic tumors. Percent survival as a function of age is shown in panel A for MT-TGFa x AL-myc and
AL-myc (line 741-3) transgenic mice and in panel B for MT-TGFa x AL-TAg and AL-TAg transgenic mice. See Table 1 for a description of
the transgenic lineages used in these crosses. (A) n = 9 for TGFa x myc and 6 for myc only; (B) n = 6 for TGFa x TAg and 15 for TAg only.
Dual-positive mouse survival is significantly reduced relative to that of the respective single-positive control for each pair at P < 0.00001,
using Student's t test.
sion relative to that in normal surrounding liver (Fig. 8).
However, there was no consistent change in the expression
of EGFR mRNA in tumors as measured by Northern blot
analysis (Fig. 8).
Sections of liver adjacent to tumors in MT-TGFa x
AL-myc mice contained multiple collections of dysplastic
hepatocytes that displayed variations in nuclear and cellular




hepatic focus was also present in almost all sections of
nontransformed liver in dual-transgenic mice at the time of
sacrifice (Fig. 6D). These foci, which were not observed in
either MT-TGFa or AL-myc single-positive mouse livers,
consisted of vacuolated cells containing a thin rim of baso-
philic cytoplasm and generally resembled clear cell foci.
When 25 of these foci were examined for the presence of
either TGFa protein or TGFa transcripts, only 2 showed
elevated expression relative to surrounding normal tissue.
Interestingly, a less common class of focus that displayed
only minor morphological alterations showed greatly ele-
vated expression of both TGFa protein and transcripts (Fig.
6E and F), suggesting that these may be preneoplastic
lesions.
Finally, we also determined that coexpression of TGFa
and TAg in liver, as in pancreas, markedly reduced trans-
genic mouse survival relative to that of mice carrying TAg
alone (Fig. 7B). However, the morphological character of
both preneoplastic lesions (altered cell foci of the clear,
eosinophilic, and basophilic types) and tumors (adenomas,
solid to trabecular carcinomas, and cholangiomas) did not
obviously differ between TGFa/TAg and TAg-only trans-
genic mice. As in the case of MT-TGFa x AL-myc tumors,




FIG. 8. Northern blot analysis of TGFa/myc-induced hepatic
tumors. Blots were probed with a labeled 2.3-kb fragment of the rat
TGFa cDNA (top), a 4.0-kb fragment of the rat EGFR cDNA, or a
0.4-kb fragment from exon 2 of the mouse c-myc gene (bottom).
Liver (nonneoplastic) and tumor RNAs from the same mouse were
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FIG. 9. Northern blot analysis of TGFaFIAg-induced hepatic
tumors. Blots were probed with a labeled 2.3-kb fragment of the
cloned rat TGFc cDNA. Liver (nonneoplastic) and tumor RNAs
from the same mouse were placed in adjacent lanes. The cysts
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tumors (though not in cystic cholangiomas) relative to levels
in neighboring nonneoplastic liver (Fig. 9), suggesting that
transgene induction is a general feature of TGFa x onco-
gene-induced hepatocarcinogenesis in the mouse.
DISCUSSION
In this report, we demonstrate that elevated expression of
TGFa under the control of heterologous promoters mark-
edly accelerates oncogene-induced tumorigenesis in two
tissues, pancreas and liver. Acting alone in these tissues,
TGFa is largely nononcogenic (pancreas) or only moderately
oncogenic, inducing tumors with relatively long latency
(liver). This finding is consistent with numerous observa-
tions that expression of TGFa is elevated in both pancreatic
and hepatic cancers as well as in transformed cell lines
derived from these tissues (3, 13, 20-22, 24, 30, 34, 45, 54).
Taken together with our previous finding that deregulated
expression of TGFa alone induces mammary cancer in
nonvirgin female mice with a high incidence (37), these
results provide clear confirmation that induced expression of
TGFa, and perhaps of related growth factors, markedly
influences tumor development in vivo. The results further
suggest that strategies to interdict TGFa-mediated autocrine
and paracrine growth loops in human tumors might prolong
patient survival.
Our data suggest that a principal consequence of deregu-
lated TGFa expression during oncogene-induced tumorigen-
esis is the enhancement of tumor growth. Thus, acting in
concert with both viral and cellular oncogenes in liver and
pancreas, TGFa dramatically stimulated growth of primary
tumors in situ as well as of tumors transplanted under the
skin of syngeneic hosts. The fact that TGFa alone had only
a moderate and generally well-regulated effect upon growth
of these organs, as shown in our previous study (37),
indicates that a significant step in oncogene-mediated tumor
progression is the loss of normal control mechanisms that
regulate signal transduction via TGFa-activated EGFR
and/or the cellular response to that signal. However, several
of the present findings suggest that in addition to its obvious
enhancement of tumor growth, TGFai may influence other
aspects of tumor development, including tumor initiation
and phenotype. For example, the marked increase in acinar
cell number in the pancreas of TGFaTAg mice between 2
and 4 weeks of age occurs just prior to the appearance of
preneoplastic foci. Since hyperplasia and tumor promotion
are strongly associated in many organs (10, 32), the in-
creased cell division in these mice may serve to both create
and permanently fix the multiple oncogenic alterations that
accumulate during oncogene-induced transformation. Also,
given the TGFa-mediated doubling of hepatocyte number
that occurs in young adult MT-TGFa transgenic mice (37),
this growth factor may act in part by simply increasing the
population of susceptible target cells. On the other hand,
despite indications that TGFa is angiogenic (42) and can
influence cell migration (2), deregulated TGFa expression in
TAg- and c-myc-induced tumors did not obviously result in
tumor hypervascularity or enhanced metastatic potential.
However, accelerated tumor growth implies accelerated
tumor vascularization, and we cannot exclude the possibility
that TGFa accomplishes the former in part by effecting the
latter.
Eviddence that TGFao can influence tumor phenotype is
provided. by the observation that TGFt/c-myc-induced tu-
mors in both pancreas and liver generally appeared more
malignant than did tumors induced by c-myc alone. This
finding is consistent with the previously postulated interac-
tion between TGFct and c-myc during hepatic carcinogene-
sis. Lee et al. (21), studying a series of 16 clonally derived
transformed rat liver epithelial cell lines, found that c-myc
expression was positively correlated with tumorigenesis in
all clones, but that TGFa expression was highly correlated
with tumorigenicity only in those clones that expressed
c-myc at levels higher than the median for all clones.
Additionally, there have been reports that c-myc overex-
pression in cultured cells amplifies the effects of autocrine
growth circuits, including those involving the EGFR (46, 47).
Thus, in the context of the additional clonal amplification of
TGFa and c-myc transgene expression that we observe in
hepatic tumors (see below), deregulated c-myc expression
may provide a permissive cellular environment for malignant
transformation by TGFa, or, conversely, high-level TGFa
induction may constitute a rate-limiting step in a c-myc-
associated transformation pathway.
A particularly striking result was the observation that
expression of the TGFa transgene in dual-positive hepatic
lesions was almost always highly induced relative to expres-
sion in surrounding tissues. Although the induction mimics
the frequently observed deregulation of endogenous TGFao
expression in neoplastic cells and tissues, it occurs in the
context of a transgene that contains the TGFa coding
sequence but that specifically lacks the TGFa enhancer/
promoter elements and 3' noncoding sequences that presum-
ably regulate expression of the endogenous gene. The finding
that induction of TGFot expression is likely to occur via
novel regulatory elements, in this case provided by the MT
gene, strongly supports the notion that induction confers a
strong selective advantage upon affected cells. Our observa-
tions of a similar induction of myc transgene expression,
which again utilized a heterologous enhancer/promoter, and
increased expression of endogenous insulin-like growth fac-
tor II in three of eight examined TGFa/c-myc-induced tu-
mors (data not shown), a common finding in other transgenic
models of mouse hepatocarcinogenesis (8, 41, 48), support
the notion that progression of hepatic tumors may be orches-
trated, in part, by a global induction of growth-promoting
genes such that tumor cells progressively become autono-
mous from exogenous growth-regulatory signals. Interest-
ingly, induction of TGFa transgene expression was not
observed in pancreatic lesions, suggesting that basal trans-
gene expression in this tissue may be sufficient to maximally
stimulate TGFa-responsive autocrine or paracrine growth
loops (20, 30, 45).
On the basis of this and other studies employing transgenic
models, we can now begin to identify the pathological effects
of deregulated TGFot expression in vivo. TGFa has a major
influence as an epithelial cell mitogen, but its ability to
induce epithelial transformation is highly tissue specific (18,
37). In mice, hepatic and mammary epithelia (18, 27, 37) and
epidermis (50) appear to be most susceptible to TGFa-
mediated neoplastic transformation, and TGFot can further
accelerate the development of hepatic tumors induced by
other oncogenes. In pancreas, a tissue that is not readily
transformed by elevated TGFa expression, this growth
factor still can have a marked influence upon late stages of
tumor development by enhancing tumor growth. By con-
ducting studies of this type, we can identify contributions of
altered gene expression to multistage carcinogenesis and
ultimately apply this knowledge to the design of specific
cancer therapy.
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